Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Spinal cord or cauda equina compression secondary to epidural metastasis rarely develops in patients with endometrial carcinoma and the early signs and symptoms of compression can therefore be inadvertently overlooked. A 78-year-old patient who developed bone metastasis with destruction of the fifth lumbar vertebral body and blockage of the cauda equina at L-4, L-5 as the only sites of metastasis is reported. This occurred 2 years after initial treatment of a stage IB, well-differentiated, grade I, adenosquamous carcinoma of the endometrium. The patient remains alive, with good neurological function and free of metastatic disease, 2 1/2 years following vertebrectomy, radiation therapy, and adjuvant Provera (medroxyprogesterone acetate) therapy. This patient represents the only case of metastatic endometrial cancer with cauda equina compression in the literature in whom long-term disease-free follow-up has been noted.
 ...
PMID:Cauda equina compression secondary to metastatic carcinoma of the uterine corpus: preservation of neurologic function and long-term survival following surgical decompression and radiation therapy. 397 89

The effects of Medroxyprogesterone acetate (MPA) and progesterone (P) on DNA and RNA contents of a human endometrial cancer cell line (Ishikawa) and a human breast cancer cell line (MCF-7) were studied using Flow cytometry. The results were as follows. MPA and P at a high dose of 10(-5) M inhibited their cell cycle progression through the G1 phase or G1-S phase boundary and showed a decrease in the number of cells which underwent DNA synthesis and mitosis. P at a low dose of 10(-7) M showed the lengthening of cell cycle time in the S phase. MPA at 10(-7) M had an inhibitory effect on the cell cycle progression of Ishikawa cells similar to that of a high dose of MPA whereas, in the case of MCF-7 cells, it showed a lengthening of duration in the S phase. Therefore, the dose-responsibility of these cells to MPA were shown to be different. A high dose of MPA and P showed a decrease in the cytoplasmic and nuclear RNA contents. A low dose of MPA and P had no marked effect on the RNA contents. From these results, it was clarified that MPA, especially at a high dose, could substantially inhibit RNA synthesis and DNA synthesis with a delay of the cell cycle progression in hormone responsive cancer cells.
 ...
PMID:[The effects of progestogens on a human endometrial cancer cell line Ishikawa and a human breast cancer cell line MCF-7]. 401 8

On the basis of a personal series of 43 cases of ovarian endometrioid carcinoma the Authors point out that this histologic type is more hormonosensitive than the other ovarian carcinomas. Their search for ER and PgR receptors in the tumour tissue showed a particularly high incidence of positive cases (81.3% and 72.1% respectively). Furthermore, the adjuvant, high-dose MAP therapy (Farlutal) obtained a high incidence of positive responses with neoplastic regression in 53.5% of the patients, all of whom were PgR-and/or ER-positive cases. 71.2% of the cases that could be followed survived at 3 years and 57.1% survived at 5 years from the beginning of the therapy. From this standpoint too, the Authors compare ovarian endometrioid carcinoma to endometrial carcinoma and believe that the determination of estrogen and progesterone receptors in the neoplastic tissue can apply to the former too as a cryterion to select patients eligible for progestinic therapy.
 ...
PMID:Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma. 622 Sep 3

This reply to a letter criticizing the author's article on Depo-Provera use which appeared in the same publication argues that proponents of Depo-Provera have misled the public about its suitability for wide use. Because many Thai women have already used Depo-Provera for a decade or more, because it takes 10 times as much Depo-Provera to produce the same blood level in monkeys as in humans, and because tribal women in Thailand weighing less than 45 kg routinely received 6 month doses of 450 mg, 3 times the 3 month dose, any difference between the doses given experimental monkeys and village women is marginal. The study by McDaniel and Potts of women with endometrial cancer hospitalized in Chiang Mai and Lumpoon Provinces which examined Depo-Provera use among them had too small a sample to detect less than a 20-fold relative risk; moreover, very few cases of endometrial cancer actually came in for treatment. Depot medroxyprogesterone acetate (DMPA) and norgesterone produce a situation similar to early menopause in which the uterus is atrophic because ovulation has ceased, but estrogen production continues and the endometrium is stimulated. Menopausal women are at high risk of developing endometrial cancer. Research literature suggests that the reproductive systems of breastfed infants are vulnerable to longterm action of DMPA in milk. Babies exposed in utero may be at risk of vaginal adenosis or cardiovascular malformations. Giving Depo-Provera to mothers of nursing babies violates the restrictions on use of children in medical experiments evolved after the Nuremburg trials. The hostility of population control activists to critics concerned about cancer evidence may prevent abnormal conditions from being looked for. It is suggested that DMPA experimenters experiment on themselves for 10 years while a moratorium on use of Depo-Provera is observed until the results are available.
 ...
PMID:Reply to Dr. Edwin B. McDaniel. Exaggerated claims of depo-provera safety. 622 51

Twenty-one women were given depot-medroxyprogesterone acetate (DMPA) 1000 mg/wk for 6 mth as part of the treatment for endometrial carcinoma in either clinical stage I or II. Total and free cholesterol, triglycerides and phospholipids were analysed in serum and in the ultracentrifugally separated lipoprotein fractions VLDL, LDL and HDL (very low, low and high density lipoproteins). Previous studies have shown little effect on lipoprotein metabolism after lower doses of MPA, unlike progestins of the 19-nor-testosterone series, after which an 'androgenic' lipoprotein pattern is seen, i.e., a decrease in HDL-cholesterol and in triglycerides in serum and VLDL. After this massive DMPA dose, only a slight decrease in HDL-cholesterol was seen, as well as a rise in triglycerides in serum and VLDL. We interpret the latter finding as secondary to an influence on carbohydrate metabolism.
 ...
PMID:High-dose depot-medroxyprogesterone acetate (DMPA) - effects on lipid and lipoprotein metabolism. 622 6

Scanning electron microscopic examination revealed conspicuous superficial changes in endometrial carcinoma, primarily in highly differentiated cases, after treatment with high doses of a progesterone compound (Depo-Provera). The most important changes included decrease of superficial structure, distruction of microvilli, loosening of intercellular connection and disintegration of the glandular substance. In consequence a barren, poorly structured, "devastated" pattern was seen, which points to the regressive processes on intracellular plane occurring on the effect of progestagens. Results confirmed the hypothesis of the close relationship between intracellular and cell surface processes.
 ...
PMID:[Cell surface changes after high-dosage progesterone treatment in endometrial carcinoma]. 623 68

The authors studied electron microscopically the effect of a large dose of medroxyprogesterone acetate (Depo-Provera) on the fine structure of endometrial carcinoma, with special regard to the annulate lamellae of the cells. Following treatment in one-third of their cases of highly-differentiated endometrial carcinoma the glandular epithelial cells were found to show a marked regression. After using a large dose of progestogen, the oestrogen-dependent annulate lamellae 'disappeared' from the cytoplasm of the cells. This phenomenon may be one of the morphological manifestations of subcellular oestrogen-progesterone antagonism.
 ...
PMID:Effect of progestogen (Depo-Provera) on annulate lamellae in endometrial carcinoma. 624 Aug 79

Currently Depo-Provera has not been approved by the FDA (Food and Drug Administration) for contraceptive use in the U.S., although USAID is allowed to distribute it for use in population programs in developing countries. The FDA denied Upjohn's petition for approval of the basis of tests showing that Depo-Provera has caused an increased incidence of mammary carcinoma in laboratory dogs. A review of additional tests conducted on laboratory animals, the results of which were not released to the public, indicates that adverse results were withheld from the public by the manufacturer. Tests with laboratory dogs and monkeys have revealed many serious side effects from the drug. Endometrial carcinoma, shortened life expectancy, interference with carbohydrate metabolism, and suppression of immune responses are the most major of these side effects. The immunosuppressive effects make women more vulnerable to infection and also seem to promote malignancy. Exposure to Depo-Provera, as to other progestogens, in utero is associated with an increased risk of congenital malformation in children. In view of the seriousness of the findings, questions are raised as to the advisability of continued contraceptive use of Depo-Provera.
 ...
PMID:Depo-Provera: a critical analysis. 645 87

The sex steroid hormone receptor levels of uterine cytosol were assayed in the course of experimental induction of endometrial carcinoma in rats. Effects of administration of various hormones on the receptor levels were examined with each histological pattern of endometrium. 1) The dissociation constants for E2 and R5020 bindings with uterine cytosol were almost fixed in spite of various histological patterns of endometrium. 2) The influence of administrated hormones on the receptor assay system could be neglected by the preincubation of uterine cytosol with DCC for five times. 3) By the administration of DES for six weeks, estrogen receptor levels were increased significantly in adenocarcinoma, while progesterone receptor levels did not show the tendency of decreasing. 4) By the administration of MPA combined with DES, estrogen receptor levels were not decreased significantly in both atypical adenomatous hyperplasia and adenocarcinoma; progesterone receptor levels were decreased in all groups. 5) By the administration of MPA, estrogen receptor levels were decreased significantly in adenocarcinoma. These data suggest that receptor levels can be controlled by the administration of sex hormones in the course of development of endometrial carcinoma.
 ...
PMID:[Changes of sex steroid hormone receptors in rat uterine cytosol during experimental induction of endometrial carcinoma (author's transl)]. 645 22

In this discussion of Depo-Provera (DMPA) attention is directed to the following: pharmacology and mode of action; clinical considerations; cervical dysplasia; breast cancer; and endometrial carcinoma. DMPA, a microcrystalline suspension of medroxy-progesterone acetate, is used widely around the world as a contraceptive, particularly in developing countries. MPA (medroxy-progesterone acetate) is a synthetic progesterone which in its mycrocrystalline depot form can be delivered by simple intramuscular injection or jet injector to that depending on the dose administered plateau contraceptive blood levels will be maintained for 90-180 days when doses of 150 mg and 300 mg respectively are used. The effect of DMPA in suppressing ovulation is at the hypothalmic level where it inhibits the gonadotrophic release responsible for the midcycle surge in luteinizing hormone responsible for ovulation. When 150 mg is administered every 3 months pregnancy rates range from 0.0-1.2/100 women years. The pregnancy rates range from 0.0-3.8/100 women years when 300 mg is administered every 6 months. The drug is usually administered initially in the first 7 days of the menstrual cycle to avoid possible effects on an established pregnancy. Menstrual disturbances are the major reason for discontinuation of DMPA. The usual side effects are amenorrhea, irregular but infrequent bleeding, and a few instances of prolonged or heavy bleeding. There is no evidence to suggest that DMPA increases the risk of invasive cancer of the cervix, but the evidence regarding the incidence of cervical dysplasia is ambiguous. There have not been any cases of breast cancer that can be related to DMPA use, but DMPA toxicology studies on beagle bitches revealed an increased incidence of benign and malignant breast tumors. It is well established that in adenocarcinoma of the endometrium DMPA is effective in causing regression and preventing recurrence of this tumor.
 ...
PMID:Depo provera in perspective. 646 84


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>